Danaher: Cytiva, HyClone, & Cell Culture Sales
Former Sales Specialist at Cytiva
inpractise.com/articles/danaher-cytiva-hyclone-and-cell-culture-sales
Danaher: Cytiva, HyClone, & Cell Culture Sales(March 13, 2024)
Former Sales Specialist at Cytiva
The executive has over 20 years biochemistry research and professional experience and is a Former Cell Culture Sales Specialist at Cytiva, responsible for selling its Hyclone product portfolio.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Why haven't larger companies like Merck, Millipore attempted to enter this market? If the technology hasn't changed for 20 years and companies like GE have a huge market share, why hasn't a competitor tried to enter this space?
They have attempted, perhaps without success. There were many patented aspects when it comes to chromatography resins. Millipore Sigma does have some resins similar to Thermo Fisher. They can compete to some extent, but Thermo Fisher has products that Cytiva cannot compete with, despite their offerings. The credibility within the customer base also plays a significant role.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Pall, Cytiva & the Bioprocessing Manufacturing Process
Former VP of Sales at Pall Corp
Danaher's Pall: Medical vs Biopharma Segment Quality
Former President at Pall
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.